anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Humulin N
Trial phase: Phase 2
ATC code: A10AE01
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: 40 IU of intranasal insulin daily Intranasal Insulin: 1.treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks; 2. placebo arm: normal saline, daily, intranasally, for 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Males or females older than 17 years.
Clinical diagnosis of Parkinson disease or multiple system atrophy.
Provide written informed consent to participate in the study.
Understand that they may withdraw their consent at any time.

Exclusion Criteria:

Women who are pregnant or lactating.
In the investigator's opinion, have significant systemic, hepatic, cardiovascular, renal or other illness that can interfere based on investigator judgment with the trial.
History of dementia.
Unable to walk without help for at least 1 minute.
History of allergic reaction to insulin.
The presence of inflammation of nasal cavity that may prevents absorption of insulin.
Intervention: Humulin N
Trial phase: Phase 2
ATC code: A10AE01
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Placebo arm using intranasal normal saline Intranasal Insulin: 1.treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks; 2. placebo arm: normal saline, daily, intranasally, for 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Males or females older than 17 years.
Clinical diagnosis of Parkinson disease or multiple system atrophy.
Provide written informed consent to participate in the study.
Understand that they may withdraw their consent at any time.

Exclusion Criteria:

Women who are pregnant or lactating.
In the investigator's opinion, have significant systemic, hepatic, cardiovascular, renal or other illness that can interfere based on investigator judgment with the trial.
History of dementia.
Unable to walk without help for at least 1 minute.
History of allergic reaction to insulin.
The presence of inflammation of nasal cavity that may prevents absorption of insulin.
Intervention: Donepezil
Trial phase: Phase 2
ATC code: N06DA02 | N06DA52 | N06DA53
SMILES: COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: During the first 4 weeks, participants received placebo for donepezil. Over the following 2 weeks, participants were treated with donepezil at 5 mg per day. Then, over the remaining 10 weeks were titrated to up to 10 mg per day donepezil based on tolerability.
Eligibility criteria:
Inclusion Criteria:

Meets listed criteria for a diagnosis of probable AD
Has a clearly documented history either in medical records or from an informant of cognitive decline over at least 6 months
Has a reliable partner/caregiver who is willing to provide input by participating in assessments
Has results of a physical examination and clinical laboratory tests within normal or clinically acceptable limits
Can communicate with trial staff acceptably, possesses the ability to respond verbally to questions, follow instructions, complete questionnaires, and adhere to visit schedules
Can read at a 9th grade level or equivalent, and has an acceptable history of academic achievement and/or employment
Has a magnetic resonance imaging (MRI) scan that rules out non-AD conditions contributing to cognitive dysfunction
Capably performs the CogState screening battery
Has adequate visual acuity and function
Females are not of childbearing potential

Exclusion Criteria:

Has ever received acetylcholinesterase inhibitors, memantine, or other symptomatic AD treatment including approved medical foods
Has an uncontrolled, clinically significant medical condition or situation within 3 months prior to screening
Has had major surgery within 3 months prior to screening
Has tested positive for human immunodeficiency virus (HIV) or has evidence of an active hepatitis B infection
Has a history of malignancy within the prior 5 years
Is unwilling or ineligible to undergo an MRI scan
Has a history of clinically important structural changes on screening MRI scan
Has a clinically important history of stroke or a diagnosis of vascular dementia
Has evidence of a clinically relevant non-AD neurological disorder
Has a history of head trauma, or serious infectious disease affecting the brain within the prior 3-5 years
Has evidence of a clinically relevant or unstable psychiatric disorder, excepting major depression in remission
Has evidence of a current episode of major depression
Has evidence of Type 4 or Type 5 Suicidal Ideation
Has clinically significant vitamin B12 or folate deficiency in the 6 months prior to screening
Is pregnant, attempting to become pregnant or is nursing children
Has used any investigational drug or participated in any other clinical trial within the prior 30 days
Has a history of alcoholism or drug dependency/abuse within the last 5 years
Has a relative contraindication to donepezil including sick sinus syndrome, third degree heart block, active gastrointestinal (GI) bleeding, Zollinger-Ellison syndrome, uncontrolled peptic ulcer disease, or uncontrolled asthma
Intervention: Prasugrel
Trial phase: Phase 4
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.

Prasugrel: Comparison of platelet reactivity between prasugrel and ticagrelor
Eligibility criteria:
Inclusion criteria:

Patients scheduled for left heart catheterization and undergoing PCI
Age 18-75 years
On aspirin (81mg) or aspirin (81mg) and clopidogrel (75mg/day)
Presence of at least one 2C19 LOF allele

Exclusion criteria:

Known allergies to aspirin, prasugrel, ticagrelor, or clopidogrel
Age >75 years
Weight <60kg
Considered at high risk for bleeding
History of ischemic or hemorrhagic stroke or transient ischemic attack
Known severe hepatic dysfunction
On treatment with oral anticoagulant therapy (Vitamin K antagonists, dabigatran, apixaban, rivaroxaban)
Use of glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)
Blood dyscrasia or bleeding diathesis
Platelet count <80x106/mL
Hemoglobin <10 g/dL.
Active bleeding or hemodynamic instability
Creatinine Clearance <30 mL/minute
Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.
Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.
Pregnant females* *Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.
Intervention: Ticagrelor
Trial phase: Phase 4
ATC code: B01AC24
SMILES: CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.

Ticagrelor: Comparison of platelet reactivity between prasugrel and ticagrelor
Eligibility criteria:
Inclusion criteria:

Patients scheduled for left heart catheterization and undergoing PCI
Age 18-75 years
On aspirin (81mg) or aspirin (81mg) and clopidogrel (75mg/day)
Presence of at least one 2C19 LOF allele

Exclusion criteria:

Known allergies to aspirin, prasugrel, ticagrelor, or clopidogrel
Age >75 years
Weight <60kg
Considered at high risk for bleeding
History of ischemic or hemorrhagic stroke or transient ischemic attack
Known severe hepatic dysfunction
On treatment with oral anticoagulant therapy (Vitamin K antagonists, dabigatran, apixaban, rivaroxaban)
Use of glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)
Blood dyscrasia or bleeding diathesis
Platelet count <80x106/mL
Hemoglobin <10 g/dL.
Active bleeding or hemodynamic instability
Creatinine Clearance <30 mL/minute
Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.
Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.
Pregnant females* *Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Normal Saline is administrated as an adjuvant of lidocaine.
Eligibility criteria:
Inclusion Criteria:

Subjects scheduled to undergo elective operation of TURBT on lateral wall for whom ONB was needed diagnosed through cystoscopy or CT examination preoperatively.
Subject's American Society of Anesthesiologists physical status is I-II.
The subject's parent/legally authorized guardian has given written informed consent to participate.

Exclusion Criteria:

Subject has a diagnosis of abnormal coagulation function.
Subject has a diagnosis of Diabetes mellitus.
Subject has a preexisting neurologic deficits of the lower extremities.
Subject has a history of alcohol or drug abuse.
Subject is pregnant or breast-feeding.
Subject is obese (body mass index >30kg/m2).
Intervention: Difamilast
Trial phase: Phase 2
SMILES: CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: OPA-15406 0.3% ointment was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
Eligibility criteria:
Inclusion Criteria:

Participants 10-70 years of age
Diagnosis of AD
History of AD for at least 3 years
AD affecting greater than or equal to 5% and less than or equal to 40% of total body surface area (BSA) at Baseline
Investigator's Global Assessment of Disease Severity score of 2 (mild) or 3 (moderate) in the selected treatment area(s)

Exclusion Criteria:

Contact or atopic dermatitis flare within 28 days of the Baseline (Day 1) visit.
Concurrent diseases/conditions and history of other diseases/conditions in the selected treatment area(s) that may have an impact on the study assessments.
Intervention: Difamilast
Trial phase: Phase 2
SMILES: CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: OPA-15406 1% ointment was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
Eligibility criteria:
Inclusion Criteria:

Participants 10-70 years of age
Diagnosis of AD
History of AD for at least 3 years
AD affecting greater than or equal to 5% and less than or equal to 40% of total body surface area (BSA) at Baseline
Investigator's Global Assessment of Disease Severity score of 2 (mild) or 3 (moderate) in the selected treatment area(s)

Exclusion Criteria:

Contact or atopic dermatitis flare within 28 days of the Baseline (Day 1) visit.
Concurrent diseases/conditions and history of other diseases/conditions in the selected treatment area(s) that may have an impact on the study assessments.
Intervention: Ciprofloxacin
Trial phase: Phase 3
ATC code: J01MA02 | J01RA10 | J01RA11 | J01RA12 | S01AE03 | S02AA15 | S03AA07
SMILES: O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Active treatment twice daily for 28 days

Ciprofloxacin: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
Eligibility criteria:
Inclusion Criteria:

HIV positive with Salivary Gland Disease
Ability to read and understand English

Exclusion Criteria:

Allergy to the family of fluoroquinolones (including ciprofloxacin)
Currently taking tizanidine
Concurrently taking antiacids containing magnesium hydroxide or aluminum hydroxide
Current use of Theophylline
Previous tendon disorder such as Rheumatoid arthritis
History of seizures
Current use of phenytoin
Current use of glyburide
Current use of methotrexate
Severe renal impairment (known creatinine clearance < 30 or on dialysis)
Intervention: Budesonide
Trial phase: Phase 2
ATC code: A07EA06 | D07AC09 | R01AD05 | R03AK07 | R03AK12 | R03AL11 | R03BA02
SMILES: CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Budesonide 1mg twice a day for a total of 8 weeks following endoscopic submucosal dissection or endoscopic mucosal resection

Budesonide: Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.

The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.

Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide.
Eligibility criteria:
Inclusion Criteria:

Age 18 years or older
Diagnosis of esophageal lesion treated with ESD or EMR which involves ≥ 50% of the esophageal circumference.

Exclusion Criteria:

Locally advanced disease
Prior esophageal surgery
Participation in another research protocol that could interfere or influence the outcome measures of the present study.
The subject or legal representative is unable/unwilling to give informed consent. (study group)
Medications or conditions for which there is a contraindication to use of budesonide (see pharmacology section below)
Concomitant use of systemic steroids or other immune suppressive medication for a different condition 9. Pregnant women
Intervention: Lovenox
Trial phase: Phase 1
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 90
Group description: This arm will have patients randomized to receive 40 mg sub-cutaneous injection of Lovenox (enoxaparin) once daily.

Enoxaparin: Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
Eligibility criteria:
Inclusion Criteria:

Women with a body mass index >35 who have undergone cesarean delivery in the last 12 hours who will receive thromboprophylaxis with enoxaparin
Subjects who consent to the study.

Exclusion Criteria:

Women with a previous history of deep venous thrombosis or pulmonary embolism
Women who are currently receiving another form of low molecular weight heparin or unfractionated heparin.
Women who are receiving other concomitant anticoagulant medications, such as warfarin, lepirudin, or argatroban.
Subjects who are unable or unwilling to give informed consent.
Women who, in the judgment of the investigators, would not be in the best interest of the patient to participate in the study.
Allergy to enoxaparin.
Women with renal impairment
Women with contraindications to Lovenox treatment such as women with active bleeding or thrombocytopenia
Intervention: Lovenox
Trial phase: Phase 1
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 90
Group description: This arm will have patients randomized to receive weight based (0.5 mg/kg) sub-cutaneous injection of Lovenox (enoxaparin) twice daily.

Enoxaparin: Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
Eligibility criteria:
Inclusion Criteria:

Women with a body mass index >35 who have undergone cesarean delivery in the last 12 hours who will receive thromboprophylaxis with enoxaparin
Subjects who consent to the study.

Exclusion Criteria:

Women with a previous history of deep venous thrombosis or pulmonary embolism
Women who are currently receiving another form of low molecular weight heparin or unfractionated heparin.
Women who are receiving other concomitant anticoagulant medications, such as warfarin, lepirudin, or argatroban.
Subjects who are unable or unwilling to give informed consent.
Women who, in the judgment of the investigators, would not be in the best interest of the patient to participate in the study.
Allergy to enoxaparin.
Women with renal impairment
Women with contraindications to Lovenox treatment such as women with active bleeding or thrombocytopenia
Intervention: Tamoxifen
Trial phase: Phase 4
ATC code: L02BA01
SMILES: CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
Sex: Female
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 56
Group description: Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.

Tamoxifen: 7 day course of tamoxifen during an episode of irregular vaginal bleeding
Eligibility criteria:
Inclusion Criteria:

Current user of the etonogestrel implant (Nexplanon, Implanon) for at least one month
Experiencing bleeding episodes more frequently than every 24 days, or a single episode of bleeding lasting longer than 14 days
English or Spanish speaking
Planning to continue implant use for six months
Access to a cell phone that can accept and send text messages

Exclusion Criteria:

Postpartum within six months
Post-abortion within six weeks
Pregnant
Breast-feeding
Undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant
Bleeding dyscrasia
Anticoagulation use
Active cervicitis
Allergy to tamoxifen
History of venous thromboembolism
Current or past breast or uterine malignancy
Use of medication contraindicated with tamoxifen (coumadin, letrozole, bromocriptine, rifampicin, aminoglutethimide, phenobarbital)
Intervention: Meropenem
Trial phase: Phase 3
ATC code: J01DH02 | J01DH52
SMILES: [H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)=C(C(=O)O)N1C(=O)[C@]2([H])[C@@H](C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 359
Group description: Participants receive 1000 mg meropenem administered as an IV infusion q8h.
Eligibility criteria:
Key Inclusion Criteria:

Adult participants diagnosed with either VABP or ventilated HABP requiring IV antibiotic therapy;
Intubated and on mechanical ventilation at the time of randomization;
New or progressive infiltrate on chest radiography consistent with pneumonia;
Presence of clinical criteria consistent with a diagnosis of ventilated nosocomial pneumonia.

Key Exclusion Criteria:

History of moderate or severe hypersensitivity reactions to beta-lactam antibiotics;
Prior non-study antibiotics for > 24 hours;
Gram stain of lower respiratory tract specimen showing only gram positive bacteria;
Active immunosuppression;
End-stage renal disease or requirement for dialysis;
Expected survival < 72 hours;
Severe confounding respiratory condition (i.e., chest trauma with paradoxical respiration);
Known or suspected community-acquired bacterial pneumonia.
Anticipated concomitant use of any of the following medications during the course of study therapy: valproic acid or divalproex sodium. Anticipated concomitant use of serotonin re-uptake inhibitors, tricyclic antidepressants, or serotonin 5-HT1 receptor agonists (triptans), meperidine, or buspirone during the course of linezolid treatment.
Receipt of a monoamine oxidase inhibitor within 14 days prior to the first dose of study drug or anticipated concomitant use during the course of linezolid therapy.